On August 22, Sonic Healthcare USA Inc. (SHUSA) announced the acquisition of Cairo Diagnostics LLC, a hematology oncology diagnostics provider based in White Plains, New York.
Cairo also operates a second laboratory in Woodcliff Lake, New Jersey. Financial terms of the transaction were not disclosed.
About Sonic Healthcare USA
Sonic Healthcare USA is the U.S. operating division of Sonic Healthcare Limited, one of the world’s largest medical diagnostics companies.
The organization is known for its clinical and anatomic pathology services, supported by a nationwide network of laboratories guided by medical leadership and local practice models.
Cairo Diagnostics’ Role in Oncology
Founded in 2013 by hematopathologist Dr. Sherif Ibrahim, Cairo Diagnostics has earned recognition for its integrated oncology approach. The laboratory combines histopathology, molecular diagnostics, cytogenetics, flow cytometry, and immunohistochemistry within a single facility.
This model reduces delays and ensures physicians receive comprehensive diagnostic insights quickly.
Impact on Oncology Testing
By consolidating multiple testing disciplines under one roof, Cairo has streamlined processes that typically require coordination across different laboratories.
This structure supports oncologists with timely, complete results — a crucial advantage in guiding treatment plans for cancer patients who cannot afford delays in diagnostic information.
Integration into Sonic’s Network
Sonic Healthcare USA intends to integrate Cairo Diagnostics’ test menu and laboratory infrastructure into its national platform. The move is expected to leverage Sonic’s existing logistics systems, payer contracting, and commercial organization to expand Cairo’s reach beyond its current regional presence.
Enhancing National Access
The integration will transform Cairo from a regional player into a national provider of advanced oncology diagnostics. SHUSA’s established specimen logistics expertise and payer relationships will enable Cairo’s services to be offered in-network to a substantial share of covered patients across the United States.
Statements from Leadership
Dr. Cory A. Roberts, CEO of Sonic Healthcare USA, emphasized the significance of the acquisition. He noted, “This acquisition reflects Sonic’s commitment to medical leadership in practice, not just in words.
By bringing Cairo’s integrated oncology platforms into Sonic’s network, we expect to support oncologists nationwide and strengthen SHUSA’s oncology capabilities.”
Commitment to Medical Leadership
Roberts highlighted that Cairo’s comprehensive diagnostic platform complements Sonic’s mission of medical leadership. The acquisition provides SHUSA with advanced oncology solutions that align with its vision of offering complex diagnostic services guided by practicing medical experts.
Perspective from the Chief Medical Officer
Dr. Mohammed Salama, Chief Medical Officer at Sonic Healthcare USA, outlined the future potential. He stated, “By combining Cairo’s comprehensive menu with SHUSA’s nationwide infrastructure, we can deliver faster, more complete answers to care teams.
This acquisition positions us to expand into areas of innovation, including liquid biopsy and other emerging technologies.”
Focus on Emerging Technologies
Liquid biopsy, an evolving diagnostic tool that detects cancer-related biomarkers from blood samples, represents a critical area of innovation. With Cairo’s integrated platforms now part of SHUSA, the company expects to position itself at the forefront of adopting these new diagnostic technologies.
Cairo’s Perspective on the Acquisition
Founder Dr. Sherif Ibrahim emphasized shared values and scalability. “For over a decade, Cairo Diagnostics has focused on bringing essential tests together under one roof and delivering results in days, not weeks,” he said. “Joining Sonic Healthcare USA allows us to extend that same quality nationwide while preserving our personal approach.”
Founder’s Background
Before establishing Cairo, Ibrahim built a distinguished career in academic medicine, holding positions at NYU, Memorial Sloan-Kettering, and MD Anderson Cancer Center. His expertise in hematopathology shaped Cairo’s mission of integrating diagnostic specialties to improve oncology care.
Benefits for Physicians
For oncologists, the acquisition provides access to a single, unified source of comprehensive diagnostic results. Instead of coordinating multiple laboratories, physicians can rely on Cairo’s integrated reports, ensuring more complete and timely data to inform treatment strategies.
Benefits for Patients
Patients are expected to benefit from expanded access to Cairo’s advanced diagnostics nationwide. Faster turnaround times for critical test results can accelerate treatment decisions, while inclusion in payer networks will improve affordability and accessibility for a broader population.
Regional Strength, National Reach
Cairo Diagnostics has been a leading oncology diagnostics provider in the New York–New Jersey–Connecticut area. With Sonic’s infrastructure, this regional strength will now scale nationally, ensuring consistent access to the same quality testing for providers and patients across the country.
Strategic Significance
The acquisition aligns with SHUSA’s strategy of building a stronger oncology diagnostics platform within its U.S. network. By integrating Cairo’s expertise with Sonic’s nationwide capabilities, the organization strengthens its position as a leader in high-complexity diagnostic testing.
Both organizations emphasized their shared commitment to quality, innovation, and medical leadership. Together, Sonic Healthcare USA and Cairo Diagnostics are positioned to advance oncology diagnostics, improve patient outcomes, and deliver faster, more integrated results for providers nationwide.
